Core Scientific stock: Revenue miss and oversold signals drive another daily loss

Traders Union
All News
Financial News
Core Scientific slides 4.97% to $15.67

Highlights

Core Scientific reported Q4 2025 revenue of $79.8 million, down 16% YoY and below analyst expectations, despite a net income boost from non-cash gains.
The company accelerated its pivot to artificial intelligence infrastructure and high-density colocation, expanding to support a 1.5-gigawatt pipeline and liquidating a large portion of Bitcoin holdings.
Core Scientific shares closed at $15.67, trading below the 20-day and 50-day moving averages, with technical indicators signaling dominant bearish momentum and high volatility within a $14.00 to $16.80 range.

Outlook pressured as weaker revenue and AI transition reshape operations

Core Scientific reported fourth-quarter 2025 financial results with revenue of $79.8 million, missing analyst estimates and reflecting a 16% decrease from the previous year. The company recorded a net income of approximately $216 million for the quarter due to non-cash gains, but posted a net loss of $288.6 million for the full year. Core Scientific accelerated its transition toward artificial intelligence infrastructure and high-density colocation services, expanding sites and infrastructure for a 1.5-gigawatt pipeline, and sold a substantial portion of its Bitcoin holdings while converting facilities to support AI workloads.

Bearish momentum intensifies as key moving averages and indicators deteriorate

Technically, CORZ is pressured below key short- and medium-term moving averages, with the 20-day ($17.38) and 50-day ($17.13) above, and holding just under the 200-day support at $15.72. Immediate resistance is defined by the Ichimoku Kijun at $17.38. Momentum indicators are cautious: MACD remains neutral and ADX points to a weak trend. Both RSI and Commodity Channel Index forecast further downside, while Stochastic RSI and Bull/Bear Power confirm oversold conditions and ongoing seller dominance intraday. The Awesome Oscillator adds to the bearish tone, as the session reflects a pronounced decline and heightened volatility, with price action remaining near session lows.

Limited upside probability as consolidation hinges on technical thresholds

The expected five-day trading range for CORZ is $14.00 to $16.80, in line with the typical volatility for the asset. The likelihood of a price increase is low (under 20%), as the MACD on the weekly chart is the only indicator providing a 'Strong Buy' signal against otherwise bearish conditions. Sideways consolidation between immediate support and resistance is the baseline scenario. A break above $17.38 would indicate a bullish shift, while a move below $15.00 could trigger additional downside.

Viktoras Karapetjanc, expert at Traders Union, sees Core Scientific showing resilience at long-term support despite recent volatility and disappointing earnings. He believes the company's shift toward AI infrastructure and high-density colocation positions it well for the future. The analyst notes that current bearish technicals may keep the stock subdued short term, but news-driven sentiment and broader market trends could boost confidence if resistance is breached. As Karapetjanc says, "If Core Scientific can hold above $15.00 and capitalize on its AI pivot, a path to recovery may open up sooner than expected."

Previously it was reported that Core Scientific Inc CORZ was trading below its short- and medium-term moving averages and hovering just above its 200-day average, highlighting persistent bearish momentum and continued downward pressure. Technical indicators, including weak momentum readings and several oversold signals (RSI, Stochastic RSI, CCI), point to sustained downside risks with immediate resistance near $17.38 and key support anchored at the long-term moving average.

Source of Data: CORZ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.